Buruli ulcer

Human Vaccines

Volumn 7, Issue 11, 2011, Pages 1198-1203

  Einarsdottir, Thorbjorg ^a   Huygen, Kris ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Attenuated vaccine; Buruli ulcer; DNA vaccine; Live; Mycobacterium ulcerans; Mycolactone; Recombinant protein vaccine; Toxin

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL VACCINE; BCG VACCINE; CARRIER PROTEIN; DNA VACCINE; LIVE ATTENUATED MYCOBACTERIUM ULCERANS VACCINE; LIVE VACCINE; MYCOBACTERIUM ULCERANS ANTIGEN 85A; MYCOBACTERIUM ULCERANS HEAT SHOCK PROTEIN 65; MYCOLACTONE; SALIVAL ANTIGEN; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

BACTERIAL VIRULENCE; BURULI ULCER; DNA IMMUNIZATION; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; MILIARY TUBERCULOSIS; MYCOBACTERIUM ULCERANS; NONHUMAN; REVIEW; TUBERCULOSIS; TUBERCULOUS MENINGITIS; UNSPECIFIED SIDE EFFECT; VACCINATION;

EID: 81855224514     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.11.17751     Document Type: Review

References (63)

1. Walsh DS, Portaels F, Meyers WM. Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection. Dermatol Clin 2011; 29:1-8; PMID:21095521; DOI:10.1016/j.det.2010.09.006.
2. Fyfe JA, Lavender CJ, Handasyde KA, Legione AR, O'Brien CR, Stinear TP, et al. A major role for mammals in the ecology of Mycobacterium ulcerans. PLoS Negl Trop Dis 2010; 4:791; PMID:20706592; DOI:10.1371/journal.pntd.0000791.
3. Stinear T, Davies JK, Jenkin GA, Hayman JA, Oppedisano F, Johnson PD. Identification of Mycobacterium ulcerans in the environment from regions in Southeast Australia in which it is endemic with sequence capture-PCR. Appl Environ Microbiol 2000; 66:3206-13; PMID:10919771; DOI:10.1128/AEM.66.8.3206-13. 2000.
4. Merritt RW, Walker ED, Small PL, Wallace JR, Johnson PD, Benbow ME, et al. Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis 2010; 4:911; PMID:21179505; DOI:10.1371/journal.pntd.0000911.
5. Johnson PD, Azuolas J, Lavender CJ, Wishart E, Stinear TP, Hayman JA, et al. Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis 2007; 13:1653-60; PMID:18217547.
6. Vandelannoote K, Durnez L, Amissah D, Gryseels S, Dodoo A, Yeboah S, et al. Application of realtime PCR in Ghana, a Buruli ulcer-endemic country, confirms the presence of Mycobacterium ulcerans in the environment. FEMS Microbiol Lett 2010; 304:191-4; PMID:20146745; DOI:10.1111/j.1574-6968.2010. 01902.x.
7. Bamberger D, Jantzer N, Leidner K, Arend J, Efferth T. Fighting mycobacterial infections by antibiotics, phytochemicals and vaccines. Microbes Infect 2011; 13:613-23; PMID:20832501; DOI:10.1016/j. micinf.2010.09.002.
8. Silva MT, Portaels F, Pedrosa J. Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect Dis 2009; 9:699-710; PMID:19850228; DOI:10.1016/S1473-3099(09)70234-8.
9. O'Brien DP, Hughes AJ. Cheng C, Henry MJ, Callan P, McDonald A, et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 2007; 186:58-61; PMID:17223763.
10. Touw J, Langendijk EM, Stoner GL, Belehu A. Humoral immunity in leprosy: immunoglobulin G and M antibody responses to Mycobacterium leprae in relation to various disease patterns. Infect Immun 1982; 36:885-92; PMID:7047400.
11. Demkow U, Bialas-Chromiec B, Filewska M, Sobiecka M, Kus J, Szturmowicz M, et al. Humoral immune response against mycobacterial antigens in bronchoalveolar fluid from tuberculosis patients. J Physiol Pharmacol 2005; 56:79-84; PMID:16204779.
12. Gooding TM, Johnson PD, Smith M, Kemp AS, Robins-Browne RM. Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun 2002; 70:5562-7; PMID:12228283; DOI:10.1128/IAI.70.10.5562-7.2002.
13. Prévot G, Bourreau E, Pascalis H, Pradinaud R, Tanghe A, Huygen K, et al. Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect Immun 2004; 72:958-65; PMID:14742541; DOI:10.1128/IAI.72.2.958-65.2004.
14. Westenbrink BD, Stienstra Y, Huitema MG, Thompson WA, Klutse EO, Ampadu EO, et al. Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana. Clin Diagn Lab Immunol 2005; 12:125-9; PMID:15642996.
15. Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T. Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep 2008; 25:447-54; PMID:18497894; DOI:10.1039/b803101k.
16. Converse PJ, Almeida DV, Nuermberger EL, Grosset JH. BCG-mediated protection against Mycobacterium ulcerans infection in the mouse. PLoS Negl Trop Dis 2011; 5:985; PMID:21423646; DOI:10.1371/journal.pntd.0000985.
17. Boulkroun S, Guenin-Mace L, Thoulouze MI, Monot M, Merckx A, Langsley G, et al. Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. J Immunol 2010; 184:1436-44; PMID:20042571; DOI:10.4049/jimmunol.0902854.
18. Kishi Y. Chemistry of mycolactones, the causative toxins of Buruli ulcer. Proc Natl Acad Sci USA 2011; 108:6703-8; PMID:21383136; DOI:10.1073/pnas. 1015252108.
19. Simmonds RE, Lali FV, Smallie T, Small PL, Foxwell BM. Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism. J Immunol 2009; 182:2194-202; PMID:19201873; DOI:10.4049/jimmunol.0802294.
20. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, Lee R, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999; 283:854-7; PMID:9933171; DOI:10.1126/science.283.5403. 854.
21. Phillips R, Sarfo FS, Guenin-Mace L, Decalf J, Wansbrough-Jones M, Albert ML, et al. Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease. J Infect Dis 2009; 200:1675-84; PMID:19863437; DOI:10.1086/646615.
22. Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P, Tanguy M, et al. Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol 2005; 7:1187-96; PMID:16008585; DOI:10.1111/j.1462- 5822.2005.00546.x.
23. Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG, Pedrosa J. Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 2007; 75:3979-88; PMID:17517872; DOI:10.1128/ IAI.00290-07.
24. Torrado E, Fraga AG, Castro AG, Stragier P, Meyers WM, Portaels F, et al. Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun 2007; 75:977-87; PMID:17145944; DOI:10.1128/ IAI.00889-06.
25. Huygen K, Adjei O, Affolabi D, Bretzel G, Demangel C, Fleischer B, et al. Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol (Berl) 2009; 198:69-77; PMID:19198877; DOI:10.1007/s00430-009-0109-6.
26. Tanghe A, Content J, Van Vooren JP, Portaels F, Huygen K. Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect Immun 2001; 69:5403-11; PMID:11500410; DOI:10.1128/IAI.69.9.5403-11.2001.
27. Diaz D, Dobeli H, Yeboah-Manu D, Mensah-Quainoo E, Friedlein A, Soder N, et al. Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans. Clin Vaccine Immunol 2006; 13:1314-21; PMID:17021247; DOI:10.1128/CVI.00254-06.
28. Pidot SJ, Porter JL, Marsollier L, Chauty A, Migot- Nabias F, Badaut C, et al. Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics. PLoS Negl Trop Dis 2010; 4:872; PMID:21072233; DOI:10.1371/journal. pntd.0000872.
29. Huygen K. Prospects for vaccine development against Buruli disease. Expert Rev Vaccines 2003; 2:561-9; PMID:14711340; DOI:10.1586/14760584.2.4.561.
30. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, Brosch R, et al. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci USA 2004; 101:1345-9; PMID:14736915; DOI:10.1073/ pnas.0305877101.
31. Mosi L, Williamson H, Wallace JR, Merritt RW, Small PL. Persistent association of Mycobacterium ulcerans with West African predaceous insects of the family belostomatidae. Appl Environ Microbiol 2008; 74:7036-42; PMID:18836026; DOI:10.1128/ AEM.01234-08.
32. Thaiss CA, Kaufmann SH. Toward novel vaccines against tuberculosis: current hopes and obstacles. Yale J Biol Med 2010; 83:209-15; PMID:21165340.
33. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect Immun 2005; 73:4676-83; PMID:16040980; DOI:10.1128/IAI.73.8.4676-83.2005.
34. Magalhaes I, Sizemore DR, Ahmed RK, Mueller S, Wehlin L, Scanga C, et al. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS ONE 2008; 3:3790; PMID:19023426; DOI:10.1371/journal. pone.0003790.
35. Von Eschen K, Morrison R, Braun M, Ofori-Anyinam O, De KE, Pavithran P, et al. The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. Hum Vaccin 2009; 5:475-82; PMID:19587528.
36. Skeiky YA, Dietrich J, Lasco TM, Stagliano K, Dheenadhayalan V, Goetz MA, et al. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine 2010; 28:1084-93; PMID:19896449; DOI:10.1016/j.vaccine. 2009.10.114.
37. van Dissel JT, Soonawala D, Joosten SA, Prins C, Arend SM, Bang P, et al. Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 2011; 29:2100-9; PMID:21256189; DOI:10.1016/j.vaccine.2010.12.135.
38. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:1240-4; PMID:15502839; DOI:10.1038/nm1128.
39. Martín C. The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG? Eur Respir J 2005; 26:162-7; PMID:15994403; DOI:10.1183/09 031936.05.00109904.
40. BCG vaccination against Mycobacterium ulcerans infection (Buruli ulcer). First results of a trial in Uganda. Lancet 1969; 1:111-5; PMID:4178240.
41. Smith PG, Revill WD, Lukwago E, Rykushin YP. The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. Trans R Soc Trop Med Hyg 1976; 70:449-57; PMID:841647; DOI:10.1016/0035-9203(76)90128-0.
42. Amofah GK, Sagoe-Moses C, Adjei-Acquah C, Frimpong EH. Epidemiology of Buruli ulcer in Amansie West district, Ghana. Trans R Soc Trop Med Hyg 1993; 87:644-5; PMID:8296362; DOI:10.1016/0035- 9203(93)90272-R.
43. Portaels F, Aguiar J, Debacker M, Guedenon A, Steunou C, Zinsou C, et al. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 2004; 72:62-5; PMID:14688081; DOI:10.1128/ IAI.72.1.62-5.2004.
44. Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, et al. Recombinant BCG exporting ESAT- 6 confers enhanced protection against tuberculosis. Nat Med 2003; 9:533-9; PMID:12692540; DOI:10.1038/ nm859.
45. Randomised controlled trial of single BCG, repeated BCG or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996; 348:17-24; PMID:8691924; DOI:10.1016/S0140-6736(96)02166-6.
46. Barreto ML, Pereira SM, Pilger D, Cruz AA, Cunha SS, Sant'anna C, et al. Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: Second report of the BCG-REVAC cluster-randomised trial. Vaccine 2011; 29:4875-7; PMID:21616115; DOI:10.1016/j.vaccine. 2011.05.023.
47. Basaraba RJ, Izzo AA, Brandt L, Orme IM. Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. Vaccine 2006; 24:280-6; PMID:16153758; DOI:10.1016/j. vaccine.2005.07.103.
48. Tanghe A, Adnet PY, Gartner T, Huygen K. A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice. Infect Immun 2007; 75:2642-4; PMID:17325046; DOI:10.1128/IAI.01622-06.
49. Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, Small PL. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol 2005; 7:1295-304; PMID:16098217; DOI:10.1111/j.1462-5822.2005.00557.x.
50. Kamath AT, Fruth U, Brennan MJ, Dobbelaer R, Hubrechts P, Ho MM, et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 2005; 23:3753-61; PMID:15893612; DOI:10.1016/j.vaccine. 2005.03.001.
51. Tanghe A, Dangy JP, Pluschke G, Huygen K. Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting. PLoS Negl Trop Dis 2008; 2:199; PMID:18350112; DOI:10.1371/journal.pntd.0000199.
52. Coutanceau E, Legras P, Marsollier L, Reysset G, Cole ST, Demangel C. Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer. Microbes Infect 2006; 8:2075-81; PMID:16781179; DOI:10.1016/j. micinf.2006.03.009.
53. Nguyen TT, Bezouska K, Vavrincova P, Sedlacek P, Hromadnikova I. Humoral response against Mycobacterium bovis Hsp65 derived fragments in children and young people with various disorders. J Immunoassay Immunochem 2008; 29:281-98; PMID:18569376; DOI:10.1080/15321810802119265.
54. Huber CA, Ruf MT, Pluschke G, Kaser M. Independent loss of immunogenic proteins in Mycobacterium ulcerans suggests immune evasion. Clin Vaccine Immunol 2008; 15:598-606; PMID:18256209; DOI:10.1128/CVI.00472-07.
55. Roupie V, Romano M, Zhang L, Korf H, Lin MY, Franken KL, et al. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect Immun 2007; 75:941-9; PMID:17145953; DOI:10.1128/IAI.01137-06.
56. Lin MY, Reddy TB, Arend SM, Friggen AH, Franken KL, van Meijgaarden KE, et al. Cross-reactive immunity to Mycobacterium tuberculosis DosR regulonencoded antigens in individuals infected with environmental, nontuberculous mycobacteria. Infect Immun 2009; 77:5071-9; PMID:19737909; DOI:10.1128/IAI. 00457-09.
57. Marsollier L, Deniaux E, Brodin P, Marot A, Wondje CM, Saint-Andre JP, et al. Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. PLoS Med 2007; 4:64; PMID:17326707; DOI:10.1371/journal. pmed.0040064.
58. Benbow ME, Williamson H, Kimbirauskas R, McIntosh MD, Kolar R, Quaye C, et al. Aquatic invertebrates as unlikely vectors of Buruli ulcer disease. Emerg Infect Dis 2008; 14:1247-54; PMID:18680648; DOI:10.3201/eid1408.071503.
59. Shen NL, Hartikka J, Horn NA, Manthorpe M, Marquet M. Development and characterization of lyophilized DNA vaccine formulations. Methods Mol Med 2000; 29:23-34; PMID:21374306.
60. Fraga AG, Cruz A, Martins TG, Torrado E, Saraiva M, Pereira DR, et al. Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression. Infect Immun 2011; 79:421-30; PMID:20974825; DOI:10.1128/IAI.00820-10.
61. Chauty A, Ardant MF, Marsollier L, Pluschke G, Landier J, Adeye A, et al. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis 2011; 52:94-6; PMID:21148526; DOI:10.1093/cid/ciq072.
62. Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, Grosset JH. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against Mycobacterium ulcerans disease in mice. PLoS Negl Trop Dis 2011; 5:933; PMID:21245920; DOI:10.1371/journal.pntd.0000933.
63. Guarner J, Bartlett J, Whitney EA, Raghunathan PL, Stienstra Y, Asamoa K, et al. Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis 2003; 9:651-6; PMID:12780997.